marijuana stocks news

Form 8-K for CV SCIENCES, INC.


11-Feb-2016

Regulation FD Disclosure

Item 7.01 Regulation FD DisclosureOn February 9, 2016, CV Sciences, Inc. formerly CannaVEST Corp. (the “Company”) issued a press release (the “Press Release”) regarding the rejection of the Company’s prepayment by one investor who acquired certain convertible promissory notes issued by the Company by assignment from the lead investor. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

CBD Unlimited, Inc.,(EDXC) to Showcase CBD Pet Products at SuperZoo Expo on August 20-22, 2019 in Las Vegas, NV

CBD Unlimited to Showcase CBD Pet Products at SuperZoo Expo on August…

Innovative Industrial Properties, Inc. (IIPR) Acquires Massachusetts and Washington Properties and Enters Into Long-Term Leases with 4Front

Innovative Industrial Properties Acquires Massachusetts and Washington Properties and Enters Into Long-Term…

Green Thumb Industries Inc. (GTII) (GTBIF) Announces Rise Effingham to Begin Adult-Use Cannabis Sales on February 29

Green Thumb Industries (GTI) Announces Rise Effingham to Begin Adult-Use Cannabis Sales…

GT Biopharma Inc. (GTBP) Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis Autoimmune Muscular Disease

GT Biopharma, Inc. Starts FDA Phase 1 Clinical Trial for Myasthenia Gravis…